{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-010802","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2025-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.988346+00:00","generated_at":"2026-05-27T05:43:39.088216+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MindMed doses first patient in Phase 3 Panorama study of MM120 for GAD; data H2 2026","bullets":["First patient dosed in Panorama, second Phase 3 study of MM120 ODT (LSD) for generalized anxiety disorder.","Study will enroll ~250 participants at US/European sites; randomized 2:1:2 to 100µg, 50µg, or placebo.","Primary endpoint: change from baseline in HAM-A at Week 12 for MM120 ODT 100µg vs placebo.","Topline data from 12-week double-blind period anticipated in second half of 2026.","Builds on positive Phase 2b results; first Phase 3 study Voyage also recently launched."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-010802","json":"https://secwatch.observer/filing/0000950170-25-010802.json","markdown":"https://secwatch.observer/filing/0000950170-25-010802.md","text":"https://secwatch.observer/filing/0000950170-25-010802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025010802/0000950170-25-010802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025010802/mnmd-20250130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T05:43:39.088216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}